Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A phase 2 trial of JYP0015 in pancreatic ductal adenocarcinoma and non-small-cell lung cancer, run by Guangzhou JOYO Pharma Co., Ltd, now recruiting.
Overview
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS is a phase 2 interventional study registered as NCT06895031 by Guangzhou JOYO Pharma Co., Ltd, with 210 participants planned, started 2025-03-31 and due to reach its primary completion in 2026-03-30. Interventions recorded: JYP0015. Conditions listed: Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC). No results are recorded here; the registry entry is the source.
Setting
A Multi-center, Open-label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JYP0015 in Advanced Solid Tumors With RAS Mutation
Phase
Phase 2
Sponsor
Guangzhou JOYO Pharma Co., Ltd
Registry
Enrolled
210